Urology News and Research

Latest Urology News and Research

Research suggests lowering cholesterol can reduce benign prostatic hyperplasia

A cholesterol-lowering drug reduced the enlarged prostates of hamsters to the same extent as a drug commonly used to treat benign prostatic hyperplasia (BPH), report researchers at Children's Hospital Boston and their colleagues in the October issue of the Journal of Urology. Together, the drugs worked even better.

22 Oct 2010

Report finds shortage of Mass. physicians is getting worse

The Boston Herald: "The state's physician shortage is getting worse -- with many practices closed to new patients and a critical need for doctors in key specialties, according to a Massachusetts Medical Society report released today. ... The most acute need is for primary-care physicians who practice family or internal medicine. The study called the shortages in those two key areas 'critical.'

21 Oct 2010

Agensys and Seattle Genetics initiate ASG-5ME phase I clinical trial for castration-resistant prostate cancer

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., and Seattle Genetics, Inc. today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of castration-resistant prostate cancer. ASG-5ME is an antibody-drug conjugate (ADC) targeting the SLC44A4 antigen and is being co-developed by both companies for the treatment of solid tumors.

21 Oct 2010

NYU Langone Medical Center announces establishment of Smilow Comprehensive Prostate Cancer Center

NYU Langone Medical Center is pleased to announce that it has established The Smilow Comprehensive Prostate Cancer Center with a $5 million gift from Joel E. Smilow, a member of the Board of Trustees at NYU Langone Medical Center and New York University. The Smilow Center is dedicated to providing comprehensive, state-of-the-art personalized care for men with prostate cancer as well as educating men and their families about the disease and the wide range of treatment options available today.

21 Oct 2010

New approaches to explore causes of autoimmunity and immune deficiency diseases

A newly identified regulatory process affecting the biology of immune system T cells should give scientists new approaches to explore the causes of autoimmunity and immune deficiency diseases.

20 Oct 2010

Salix acquires rights to colon cancer screening agent from Photocure

Salix Pharmaceuticals, Ltd. today announced that the Company has acquired rights to Lumacan™ from Photocure, a Norwegian specialty pharmaceutical company. Lumacan is a novel agent designed to assist in the detection of precancerous and cancerous lesions in the colon.

20 Oct 2010

Dexamethasone improves quality of life after laparoscopic gallbladder surgery

A study presented at the American Society of Anesthesiologists 2010 Annual Meeting in San Diego seems to confirm that a single, small dose of the steroid dexamethasone improves the post-surgical quality of life of patients receiving laparoscopic gallbladder surgery.

20 Oct 2010

BCAN holds regional Bladder Cancer Patient Forum at New York Academy of Medicine

Bladder cancer is the fifth most commonly diagnosed cancer in the United States, yet most people know nothing about it. To help enhance the public's understanding of the risks and signs of bladder cancer and the importance of early detection and treatment options, the Bladder Cancer Advocacy Network (BCAN) will hold its regional Bladder Cancer Patient Forum "Understanding Bladder Cancer" on Saturday, October 23, 2010, in New York City at the New York Academy of Medicine.

20 Oct 2010

OncoGenex announces pricing of public offering

OncoGenex Pharmaceuticals, Inc. today announced that it has priced a public offering of 3,174,602 units, with each unit consisting of one share of the Company's common stock and one-half (1/2) of one warrant, at a purchase price of $15.75 per unit for an aggreate offering amount of $50 million.

20 Oct 2010

Reports examine drug company payments to doctors

ProPublica: "Drug companies say the millions of dollars they pay physicians for speaking and consulting justly compensates them for the laudable work of educating their colleagues. But a series of lawsuits brought by former employees of those companies allege the money often was used for illegal purposes — financially rewarding doctors for prescribing their brand-name medications.

20 Oct 2010

ProBuild raises $275,000 for City of Hope

ProBuild Company LLC, one of the nation's largest suppliers of building materials to professional contractors, continued its commitment to further cancer and diabetes research by hosting its 2010 Charity Golf Tournament at The Omni Interlocken Resort and Hotel in Broomfield, Colo. ProBuild and its supply partners from across the Rocky Mountain Region together raised more than $275,000 for City of Hope, one of the nation's leading research and treatment centers for cancer, diabetes and other life-threatening diseases.

19 Oct 2010

Robot-assisted surgery effective for five-year prostate cancer control: Study

A first-ever, long-term study of patients who underwent robot-assisted surgery to remove their cancerous prostates found that nearly 87 percent of them had no recurrence of the disease after five years.

19 Oct 2010

OncoGenex announces public offering of common stock

OncoGenex Pharmaceuticals, Inc. today announced that it is commencing a public offering of its common stock and warrants to purchase shares of its common stock.

19 Oct 2010

Abreu btt 700 System for continuous temperature monitoring launched at ASA Annual Meeting

Conquering the last frontier for monitoring vital signs, Brain Tunnelgenix Technologies Corp. is introducing the Abreu btt™ 700 System for continuous temperature monitoring at the Annual Meeting of the American Society of Anesthesiologists (ASA) today. The Abreu btt 700 System sensor is approved by the U.S. Food and Drug Administration for placement on the skin and to be used during surgical procedures, recovery room, intensive care and general patient monitoring.

18 Oct 2010

Elective surgeries routed to private health system to ease burden

According to the Australian Medical Association, the ACT Government's elective surgery plan is not a long term solution. The plan will see 200 public patients undergoing elective surgery at two private health facilities. The Government has planned to clear up the backlog of elective surgery by using the private health system. At present there is a focus on ear, nose and throat procedures, urology and orthopedic procedures.

17 Oct 2010

EC grants orphan medicinal product designation to Allos' pralatrexate for Hodgkin lymphoma

Allos Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan medicinal product designation for pralatrexate for the treatment of Hodgkin lymphoma (HL). The Company is currently investigating pralatrexate in a number of ongoing studies, including a Phase 2 clinical study in patients with relapsed or refractory non-Hodgkin lymphoma or Hodgkin lymphoma.

15 Oct 2010

Watson Laboratories receives FDA approval for Amlodipine capsules

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Amlodipine Besylate/Benazepril 5/20mg, 10/20mg, 2.5/10mg, and 5/10mg capsules, the generic equivalent to Novartis' Lotrel capsules.

15 Oct 2010

FDG positron emission tomography allows early diagnosis of gall bladder cancer

Researchers at the University of Granada and the Department of Nuclear Medicine, Hospital Virgen de las Nieves at Granada found that the metabolic imaging diagnosis technique based on the analysis of a structural analog of glucose labeled with a positron-emitting compound (18F) allows early diagnosis of gall bladder cancer, a relatively rare disease with high mortality rates among most patients suffering from it.

15 Oct 2010

NinePoint announces completion of $33 million Series A financing

NinePoint Medical, Inc., an emerging leader in the development of in vivo pathology devices, today announced it has completed a $33 million Series A financing led by Third Rock Ventures and Prospect Venture Partners. The company also announced the establishment of its corporate headquarters in Cambridge, Mass. where Charles Carignan, M.D., serves as president and chief executive officer.

14 Oct 2010

FREE educational program to explore discoveries and treatments on women's health issues

A variety of women's health issues occur as the result of stress or from natural functions like aging, childbirth and pregnancy. Urinary incontinence and pelvic prolapse, alterations to female aesthetic appearance and changes to the face, body and breast may result from these normal occurrences.

14 Oct 2010